Table 2.
Estimates of HDV prevalence in the general population, by WHO regiona.
| AFR | AMR | EMR | EUR | SEAR | WPR | Global | |
|---|---|---|---|---|---|---|---|
| Population (thousands) | 1,052,766 | 1,006,458 | 715,425 | 928,490 | 1,982,239 | 1,945,717 | 7,631,091 |
| HBsAg prevalence, % (95% CI) | 6.1 (4.6–8.5) | 0.7 (0.4–1.6) | 3.3 (2.6–4.3) | 1.6 (1.2–2.6) | 2.0 (1.5–4.0) | 6.2 (5.1–7.6) | 3.5 (2.7–5.0) |
| Anti-HDV prevalence among people with HBsAg, % (95% CI) | 6.0 (5.0–7.2) | 5.9 (3.0–9.7) | 3.5 (2.1–6.3) | 3.0 (2.1–4.2) | 3.2 (0.4–12.4) | 4.1 (3.5–4.8) | 4.5 (3.6–5.7) |
| Anti-HDV prevalence among the general population, % (95% CI) | 0.36 (0.26–0.54) | 0.04 (0.02–0.11) | 0.12 (0.07–0.23) | 0.05 (0.03–0.09) | 0.06 (0.01–0.35) | 0.25 (0.20–0.33) | 0.16 (0.11–0.25) |
| HDV RNA prevalence among people with anti-HDV, % (95% CI) | 41.3 (31.8–51.1) | 64.2 (21.5–98.0) | 49.4 (30.1–68.7) | 64.1 (54.3–73.3) | 50.1 (31.4–70.3) | 73.3 (57.8–68.7) | 58.5 (52.4–64.5) |
| HDV RNA prevalence among the general population, % (95% CI) | 0.15 (0.10–0.24) | 0.03 (0.01–0.09) | 0.06 (0.03–0.12) | 0.03 (0.02–0.06) | 0.03 (0.00–0.18) | 0.19 (0.13–0.26) | 0.09 (0.07–0.15) |
| Number of people with anti-HDV, thousands, % (95% CI) | 3,835 (2,779–5,706) | 416 (185–1,135) | 836 (482–1,610) | 445 (293–833) | 1,267 (172–6,841) | 4,935 (3,836–6,391) | 11,992 (8,662–18,743) |
| Number of people with HDV RNA, thousands, (95% CI) | 1,584 (1,059–2,506) | 267 (78–881) | 413 (203–877) | 285 (184–544) | 635 (83–3,622) | 3,617 (2,583–4,971) | 7,015 (4,994–11,109) |
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asian Region; WHO, World Health Organisation; WPR, Western Pacific Region.